Patrick Moran interviewed on Life Science Success
Pebble Life Science recently showcased our cutting‐edge research on the Life Science Success podcast, where our founder, Patrick Moran, provided an insightful overview of our pioneering work. Patrick’s discussion highlighted how our unique approach is not only advancing therapies for neurological conditions but is also making significant strides in the field of oncology.
Our journey began with a bold vision to harness the potential of natural product isolates. Sparked by the legalization of non-psychotropic hemp under the 2018 Farm Bill, Pebble seized the opportunity to explore novel cannabinoid and terpene combinations. Initially focused on addressing unmet needs in neurological disorders, our research soon revealed promising applications in oncology—a field that continues to present some of the most complex challenges in medicine.
Central to our work is the development of a new treatment modality aimed at targeting solid tumor cancers. By leveraging natural botanical isolates processed to pharmaceutical-grade standards, we are creating single agent and two-agent combination therapies designed to overcome drug resistance—a leading cause of cancer recurrence and treatment failure. Patrick described our breakthrough approach:
“We are developing a new modality—one that not only targets solid tumors but also integrates seamlessly with existing therapies like chemotherapy and radiotherapy.”
This approach has led us to develop three Minimum Viable Products (MVPs); providing monotherapy, adjuvant and combination treatment potential, to capture as much as possible of the 100 billion dollar market opportunity in overcoming cancer drug resistance.
Our oncology research is built upon rigorous scientific principles and an innovative mindset. We recognized early on that many current cancer treatments offer only incremental improvements. Instead, our strategy is to create transformative therapies by combining natural product safety and efficacy with the precise targeting capabilities of modern drug development. This bridging strategy enables our treatments to potentially act both as monotherapies and synergistically with conventional cancer therapies—enhancing their effectiveness while reducing toxicity. Our internal case study infrastructure, validated by third-party studies, has been instrumental in documenting the anti-inflammatory and anti-tumor potential of our compounds, setting the stage for a new wave of oncologic treatments.
The research at Pebble Life Science is a true melding of Eastern and Western medicinal philosophies. Drawing on decades of scientific literature—including reports from the National Cancer Institute—we meticulously validate our therapeutic candidates. This approach not only accelerates our discovery process but also underpins our commitment to rigorous, evidence-based innovation.
“What we bring to the table is a comprehensive understanding of natural product efficacy and the determination to execute a strategy that bridges conventional and alternative therapies,”
Patrick explained. This mindset is key to overcoming one of the most daunting challenges in oncology: drug resistance.
Collaboration is another cornerstone of our success. By partnering with leading researchers and institutions, we’ve been able to refine our prototypes and integrate emerging technologies to further enhance our drug development process. These strategic partnerships are critical as we continue to refine our treatment protocols and prepare for the next phase of clinical development.
For anyone interested in the future of oncology and the transformative potential of natural products, our interview on the Life Science Success podcast is a must-listen. Patrick’s insights offer a glimpse into the rigorous research, innovative strategies, and unwavering commitment driving Pebble Life Science. We invite you to explore the full conversation and learn how our work is poised to reshape cancer treatment and improve patient outcomes.
